Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intensity Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing intratumoral cancer therapies led by INT230-6. Form 8-K reports furnish operating results, financial-condition updates, investor-presentation materials, and clinical-development summaries tied to the company’s non-covalent drug-conjugation platform and oncology studies.
The filing record also covers capital-structure and public-company matters, including an at-the-market common stock offering program, amendments related to a reverse stock split, Nasdaq minimum-bid-price compliance, and modifications to security-holder rights. Proxy materials describe annual meeting proposals, board elections, independent auditor ratification, and amendments to equity compensation and employee stock purchase plans.
Intensity Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held via live webcast. A total of 1,079,494 shares of common stock, representing approximately 40.74% of shares entitled to vote, were present, establishing a quorum.
Stockholders elected Dr. Emer Leahy and Lewis H. Bender as Class III directors to serve until the 2029 annual meeting. They also ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved an amendment to the 2021 Stock Incentive Plan to add 150,000 shares and an amendment to the 2024 Employee Stock Purchase Plan to add 25,000 shares for issuance. They further approved the potential adjournment of the meeting, if necessary, to solicit additional proxies on the listed proposals.
Intensity Therapeutics, Inc. reported first quarter 2026 results and provided a clinical update. Net loss narrowed to $2.4 million for the three months ended March 31, 2026, compared with $3.3 million a year earlier, as lower research and development spending offset bonus accruals.
Research and development expenses were $1.2 million versus $2.2 million in 2025, while general and administrative expenses were $1.3 million versus $1.2 million. Cash and cash equivalents totaled $10.2 million as of March 31, 2026. Early data from the Phase 2 INVINCIBLE-4 TNBC study showed higher pathological complete response rates and fewer severe adverse events in patients receiving INT230-6 before standard of care, and regulators approved resumption of enrollment. The company also plans to restart limited U.S. enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study by the third quarter of 2026.
Intensity Therapeutics, Inc. reported a first‑quarter 2026 net loss of $2.4 million, narrowing from $3.3 million a year earlier, as operating expenses fell to $2.5 million from $3.4 million.
Research and development spending dropped 45% to $1.2 million, mainly from pausing its Phase 3 INVINCIBLE‑3 sarcoma trial and adjusting the INVINCIBLE‑4 breast cancer study. Cash and cash equivalents were $10.2 million as of March 31, 2026, with an accumulated deficit of $80.8 million. The company states there is substantial doubt about its ability to continue as a going concern without additional capital and is relying on equity offerings, including an expanded at‑the‑market program of up to $60.0 million, to fund late‑stage oncology trials.
Intensity Therapeutics, Inc. is asking stockholders to vote at its 2026 annual meeting, which will be held virtually via live audio webcast on June 16, 2026 at 10:30 a.m. Eastern Time. Holders of common stock at the close of business on April 23, 2026 may vote.
Stockholders are being asked to elect two directors for three-year terms ending in 2029, ratify the appointment of EisnerAmper LLP as independent registered public accounting firm for the year ending December 31, 2026, and approve amendments to two equity plans. The Company seeks to add 150,000 shares of common stock to the 2021 Stock Incentive Plan and 25,000 shares to the 2024 Employee Stock Purchase Plan.
The board also requests authority to postpone or adjourn the meeting if additional proxies are needed or a quorum is not present. The proxy statement describes voting methods, virtual meeting access and detailed information on board structure, executive compensation and ownership.
BENDER LEWIS H reported acquisition or exercise transactions in this Form 4 filing.
INTENSITY THERAPEUTICS, INC. President and CEO Lewis H. Bender received a grant of 37,749 shares of common stock at $6.11 per share as a fully vested stock award under the company’s 2021 Stock Incentive Plan. The award was made in partial satisfaction of his 2025 bonus, in lieu of cash, at his request. Following this grant, he holds 118,549 common shares directly, with all amounts adjusted for a 1-for-25 reverse stock split effected on February 18, 2026.
Intensity Therapeutics reported a narrower 2025 net loss of $11.6M, improved from $16.3M in 2024, as research and development and general and administrative expenses declined. The company raised over $20M during 2025, ending the year with $11.9M in cash and cash equivalents and a stated cash runway into the second quarter of 2027.
Clinically, preliminary data from the INVINCIBLE-4 breast cancer study showed a pathological complete response rate of 71.4% (5/7) for patients receiving INT230-6 plus standard of care versus 33% (2/6) for standard of care alone, with fewer severe adverse events. A Lancet eBioMedicine publication from the IT-01 study reported a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated metastatic patients. The INVINCIBLE-3 phase 3 sarcoma trial remains paused for new enrollment due to prior funding constraints, though the company continues treating enrolled patients and plans to restart once additional funding is obtained.
Intensity Therapeutics files its annual report describing a late-stage oncology pipeline built around lead intratumoral candidate INT230-6, which combines cisplatin, vinblastine and an amphiphilic enhancer to kill solid tumors locally while stimulating systemic immune responses.
The report highlights completed Phase 1/2 and Phase 2 data showing substantial tumor necrosis, abscopal effects and a generally favorable safety profile, with over 95% of active agents retained in tumors. Ongoing programs include the Phase 3 INVINCIBLE-3 trial in metastatic soft tissue sarcoma and the Phase 2 INVINCIBLE-4 trial in presurgical triple‑negative breast cancer, both designed around dosing based on tumor burden.
Due to funding constraints, new site activations and enrollment in INVINCIBLE-3 and enrollment in INVINCIBLE-4 were temporarily paused, although already-enrolled patients continue treatment and Swiss regulators have approved a revised dosing regimen for INVINCIBLE-4. As of March 26, 2026, the company had 2,540,518 common shares outstanding after a 1-for-25 reverse stock split.
Intensity Therapeutics, Inc. expanded the capacity of its existing at-the-market stock offering program to $60.0 million through a new prospectus supplement. This program lets the company sell common shares from time to time through H.C. Wainwright & Co. LLC.
The company is under no obligation to issue any shares and will decide whether to use the facility based on market conditions and strategic priorities. Management describes the expanded ATM as a way to enhance financial flexibility, giving the company an efficient mechanism to access equity capital if and when it chooses.
Intensity Therapeutics supplements its July 11, 2024 sales agreement to increase the ATM offering size to up to $60,000,000, effective March 23, 2026. The company has previously sold 1,297,655 shares under the agreement for an aggregate gross sales price of $12,029,360.
The ATM Offering remains an at-the-market program through H.C. Wainwright & Co., LLC under the previously disclosed Offering Agreement; all other terms remain unchanged.